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Abstract
Background: Gene therapy has been hampered by low expression upon in vivo delivery. Using a somatostatin
receptor type 2 (SSTR2)-based reporter, we assessed whether angiotensin II (AII) can improve gene expression by
adenovirus upon intra-arterial (IA) delivery in a large animal model.
Methods: A SSTR2-based reporter that can be imaged by a clinically approved radiopharmaceutical was used to
assess gene expression. Eight rabbits bearing VX2 tumors in each thigh were randomly injected IA with adenovirus
containing a human SSTR2 (Ad-CMV-HA-SSTR2) gene chimera ± AII or control adenovirus containing green
fluorescent protein (Ad-CMV-GFP). Three days later, 111In-octreotide was given IV after computed tomography (CT)
imaging using a clinical CT scanner and intravenous contrast. Tumor uptake of 111In-octreotide was evaluated the
next day using a clinical gamma camera. Gene expression was normalized to tumor weight and morphology from
CT to obtain in vivo biodistribution.
Results: SSTR2-based expression was readily visualized. VX2 tumors infected with Ad-CMV-HA-SSTR2 upon
intra-arterial delivery with AII had greater in vivo biodistribution, thus greater gene expression, than those without
AII (p < 0.01, n = 6). VX2 tumors infected with Ad-CMV-HA-SSTR2 upon IA delivery had greater biodistribution, thus
greater gene expression, than those with the negative control Ad-CMV-GFP (p < 0.02). Similarly, VX2 tumors infected
with Ad-CMV-HA-SSTR2 upon IA delivery with AII had greater biodistribution, thus greater gene expression, than
those with the negative control Ad-CMV-GFP (p < 0.01).
Conclusions: Angiotensin II improves in vivo gene expression by adenovirus upon intra-arterial delivery and thus
may improve gene therapy efficacy. In vivo SSTR2-based reporter imaging can be used to compare methodologies
for improving gene expression.
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Background
Two of the major limitations to gene therapy have been
delivery and an inability to monitor exogenous gene ex-
pression in vivo. For the former, the vector may be deliv-
ered by direct injection into the parenchyma of the
tumor or organ of interest, via inhalation, intravenously,
or intra-arterially. Systemically, venous delivery requires
first pass through the lungs and/or the liver, where the
vector may become entrapped or infect; thus, much of
the vector, such as commonly clinically used adenovirus,
may not be delivered to the tumor or organ of interest
and expression may occur in the wrong location for effi-
cacy. Arterial delivery may be used to direct the vector
to the organ or tumor of interest, particularly when de-
livery is directed via a catheter to the primary artery
feeding the tumor. Even with this approach, expression
may not be greater than intra-tumoral delivery [1].
Whether pharmacologic manipulation can increase ex-
pression upon intra-arterial adenovirus delivery needs
exploration.
Numerous vasoactive agents have been evaluated using
pharmacoangiography to modify tumor blood flow in an
effort to improve diagnosis and treatment [2, 3]. Of the
vasoconstrictors tested, angiotensin II (AII) was found
superior diagnostically, especially for poorly vascularized
tumors supplied by small arteries [2]. Subsequently, se-
lective arterial infusion of AII was investigated as a way
to maximize tumor delivery of chemotherapeutic agents
and minimize distribution to non-tumor regions [4–8].
Since blood vessels in tumors, including VX2 rabbit tu-
mors, commonly lack smooth muscle [9, 10], theoretic-
ally, arterial infusion of vasoconstricting agents should
constrict normal vessels but leave tumor vessels un-
affected, shunting blood from normal tissues to tumor.
We recently demonstrated that at an optimal dose of
2.5 μg/ml, AII increases perfusion of VX2 tumor versus
normal tissue by increasing tumor blood flow and blood
volume but decreases mean transit time [11]. Whether
angiotensin II can increase expression upon intra-
arterial adenovirus delivery needs further evaluation.
To address such questions and to monitor gene ther-
apy, there is a need to noninvasively locate, quantify, and
longitudinally assess expression after delivery. Clinically,
exogenous gene expression is most commonly followed
by biopsy; however, the entire lesion or organ is not
evaluated, there is potential for sampling error, and re-
peated analysis is difficult because of the potential for
adverse complications and patient compliance. Noninva-
sive imaging presents a means to overcome these prob-
lems by monitoring and quantifying gene expression
through the use of a reporter-based system. Reporter
genes commonly encode enzymes, transporters, or re-
ceptors [12–18] which entrap a radiopharmaceutical that
can be used for imaging.
Human somatostatin receptor type 2 (SSTR2)-based
reporter systems can be used to visualize exogenous
gene expression. We have demonstrated that a combin-
ation of anatomic and functional imaging can be used to
quantify SSTR2-based gene expression [18–20] in small
animal models using the FDA-approved radiopharma-
ceutical 111In-octreotide. Such models were primarily
studied using dedicated small animal equipment. In such
models, the small vessel size restricts catheter-based ac-
cess and vascular manipulation. The large animal VX2
rabbit tumor model allows catheterization [1] using hu-
man catheters, vascular manipulation, and imaging using
clinical machines and thus can be used to study the ef-
fect of pharmacologic vascular manipulation like AII on
gene expression. Gene therapy has been hampered by
low levels of gene expression upon in vivo delivery.
Using a SSTR2-based reporter, we assessed whether
angiotensin II can improve gene expression by adeno-




Ad-CMV-HA-SSTR2 was constructed and expression
was confirmed by in vitro experiments as previously de-
scribed [18]. The control adenovirus contained a CMV
promoter with green fluorescent protein (Ad-CMV-
GFP). Both viruses were purified and amplified by the
Vector Core lab at UT MD Anderson Cancer Center.
VX2 tumors are carried as tumor implants and not as
cell lines. Immunofluorescence imaging was performed
using HT1080 fibrosarcoma cells (ATCC, Rockville,
MD) as described [21].
Animal and tumor model
Nine New Zealand white rabbits (Myrtle’s Rabbitry,
Thompsons Station, TN) weighing 3 to 4.5 kg and rabbit
VX2 carcinoma cells were used in this study. The VX2
cells were grown by implanting into the hind limb of
several donor rabbits. When the resulting tumors
reached 2 cm in diameter, the tumors were freshly har-
vested under sterile conditions, minced, and homoge-
nized in DMEM/F12 containing 10 % FBS (Media Tech
Inc., Manassas, VA) and gentamicin. The tumor frag-
ments were aliquoted into 12 × 75 mm plastic tubes and
stored at −80 °C until further use [11]. When needed,
they were thawed, suspended in DMEM/F12 containing
10 % FBS and gentamicin, and then drawn into a 1-cc
syringe with an 18-gauge needle. A total of 0.6 ml of ho-
mogenized VX2 tumor cells were implanted in both
thighs of each experimental rabbit [1]. All animals re-
ceived humane care in compliance with the Institutional
Animal Care and Use Committee of The University of
Texas MD Anderson Cancer Center.
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Imaging and biodistribution
Nine adult New Zealand white rabbits were used to as-
sess reporter gene expression in VX2 carcinoma after
intra-arterial (IA) in vivo gene transfer. The VX2 carcin-
oma was implanted intramuscularly into both thighs of
each animal (18 tumors total). Unfortunately, one rabbit
died for unknown reasons after tumor implantation. A
total of 16 tumors from eight rabbits were utilized for
this study. After 10–12 days, multi-slice helical com-
puted tomography (CT) imaging without and with intra-
venous contrast enhancement was performed in a
supine position to confirm tumor formation and to cal-
culate tumor weight and volume [1].
Each tumor was assigned an adenovirus delivery plus
or minus AII. Six tumors underwent IA delivery (see
below) of AII and Ad-CMV-HA-SSTR2, six with Ad-
CMV-HA-SSTR2, and four tumors with Ad-CMV-GFP
as control (100 μl each, MOI 10). Tumors in the same
animal received any two of the above treatments, i.e.,
one treatment in the right leg tumor and a different
treatment in the left leg tumor. Three days later, CT im-
aging was repeated and the animals were injected via a
marginal ear vein with 22 MBq (600 μCi) of 111In-
octreotide (Octreoscan, Mallinckrodt, St. Louis, MO).
The following day, planar gamma camera imaging was
performed. The amount of 111In-octreotide in each
tumor was determined from the planar images and nor-
malized to the tumor weight (%ID/g) calculated from
the CT images [1]. After imaging, the rabbits were sacri-
ficed with an intravenous overdose of Beuthanasia-D.
Portions of tumor or organs were dissected and weighed;
the amount of radioactivity was measured using a γ-
counter to determine 111In-octreotide biodistribution
in %ID/g.
Intra-arterial route of injection
Vascular access was obtained as described [1]. Briefly,
each rabbit was sedated using isoflurane (5 %)/oxygen
(1.5 l/min) via mask administration. An endotracheal
tube was inserted, and anesthesia was maintained with
isoflurane (3–4 %)/oxygen (1.5 l/min). The antibiotic
Enrofloxacin (Baytril; Bayer Corp; Agriculture Division,
Animal Health, Shawnee Mission, KS) was given intra-
muscularly (5 mg/kg), and the neck was shaved and pre-
pared for aseptic surgery using alcohol and Betadine
scrub. A small midline incision was made to isolate and
cranially ligate the right common carotid artery. Prox-
imal to the ligation, a small arteriotomy was made to in-
sert a 4.0-F sheath (Cook Incorporated, Bloomington,
IN) into the vessel, where sodium heparin (100 IU/kg)
was administered. A 2.8-F microcatheter (EmboCath;
BioSphere Medical, Rockland, MA) was inserted through
the sheath and directed down the aorta to its bifurcation
using fluoroscopic monitoring. The catheter was then
manipulated into each external iliac artery. In order to
assess vascular anatomy and tumor location, digital sub-
traction arteriography was performed by injecting radio-
graphic contrast medium, meglumine-diatrizoate (Conray
60 %; Mallinckrodt Inc., St Louis, MO), and by hand using
fluoroscopic guidance. The microcatheter was then posi-
tioned into the deep femoral artery, which is the main, if
not exclusive, artery supplying the tumor. The catheter
was flushed with saline first, and then 100 μl (MOI of 10)
of adenovirus with or without 2.5 μg/ml angiotensin II
(GenScript USA, Piscataway, NJ) in 10 ml saline was
slowly injected; the catheter was flushed once again
with saline. Angiotensin II has an approximately 15-s
half-life [22]. The catheter was then manipulated into
the deep femoral artery in the opposite thigh, and the
process was repeated. Then, the catheter and intro-
ducer sheath were removed, the carotid artery was li-
gated proximal to the arteriotomy, and the incision
was closed in two layers.
Computed tomography imaging
All multi-slice helical computed tomography (CT)
(Lightspeed Plus; GE Medical Systems, Milwaukee, WI)
imaging was obtained using the following parameters:
120-kVp tube voltage, 80-mA tube current, 25-cm field
of view, and 1.25-mm slice thickness. For contrast-
enhanced CT imaging, 8.0 ml of Visipaque 320 contrast
medium (iodixanol; GE Healthcare, Inc., Princeton, NJ)
was injected through a marginal ear vein at a rate of
1.5 ml/s. After a 9-s delay, CT images of the thighs were
acquired.
In order to determine tumor volume and weight, a re-
gion of interest (ROI) was drawn around the entire
tumor as visualized on the CT images with or without
contrast enhancement. Tumor volume was calculated as
previously described [1] using volume viewer application
software for CT (Voxtool 3.0.64z, GE Medical Systems).
Assuming a tumor density of 1.0 g/ml, tumor volume
(cm3) was converted to tumor weight. A similar process
was used to trace and calculate the weight of necrotic
tissue within the tumor images identified as tumor areas
that did not enhance after contrast administration. The
weight of the necrotic tissue was then subtracted from
the tumor weight to calculate the weight of the tumor
without necrosis [1, 20].
Planar gamma camera imaging
The rabbits were positioned 2 cm directly below a
medium-energy parallel-hole collimator [1]. Planar im-
aging was performed for 30 min with a clinical flexible
single-head gamma camera (Digirad Corporation,
Poway, CA). The resulting images were transferred
and processed in DICOM format to an eSoft work-
station. For each animal, a ROI of the same size was
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drawn on both the tumor and background regions to
determine the average counts per pixel; radiopharma-
ceutical uptake by tumors in microCi were calculated
from correlation equations derived from microCi ver-
sus counts per pixel graphs created using phantoms
containing different amounts of 111In-octreotide in a
total volume of 500 μl [20].
Western blot
Proteins extracted from tumors infected IA with and
without AII-Ad-CMV-HA-SSTR2 or Ad-CMV-GFP con-
trol were used to perform western blotting [1] using a
mouse-anti HA antibody (Covance, Princeton, NJ) at
1:500 dilution and a secondary goat anti-mouse antibody
(Santa Cruz, Santa Cruz, CA) at 1:3000 dilution.
Statistical analysis
A power calculation determined that with alpha = .05, a
sample size of 4 would provide >80 % power to compare
groups. The data are presented as mean ± standard devi-
ation. Two-tail Student’s t test was used for making
comparisons between the groups and were analyzed
using Microsoft Excel 2007 (Microsoft Corp., Redmond,
WA). The primary comparison was Ad-CMV-HA-
SSTR2 plus versus minus AII. p < 0.05 was considered
statistically significant.
Results
Ad-CMV-HA-SSTR2 results in HA-SSTR2 expression in vitro
The VX2 tumors are carried as tumor implants and not
as cell lines. To confirm virus expression of HA-SSTR2,
HT1080 cell lines were used. Immunofluorescence im-
aging demonstrated expression of HA-SSTR2 on the cell
membrane as expected (Fig. 1). In comparison, no ex-
pression was seen in the control uninfected cells. This is
consistent with previous findings demonstrating HA-
SSTR2 expression with this virus [18].
Angiotensin II results in increased blood flow to the
tumor
Infusion of the vasoconstrictor AII at a dose of 2.5 μg/ml
into the vessel resulted in visualization of more vessels at
fluoroscopy, when compared to the no AII (Fig. 2). The
“tumor blush” is consistent with increased blood flow to
the tumor upon AII infusion and is consistent with our
previous findings suggesting increased tumor blood flow
and tumor blood volume upon angiotensin II exposure at
2.5 μg/ml [11].
Morphological assessment of reporter gene expression
after in vivo gene transfer
Three days after adenovirus infection, representative axial
CT images of VX2 tumors were obtained with and with-
out intravenous contrast enhancement (Fig. 3). In vivo
unenhanced CT imaging demonstrated areas of low at-
tenuation, but areas of necrosis could not be distinguished
(Fig. 3a). On the other hand, contrast-enhanced imaging
(Fig. 3b) illustrated peripheral rim enhancement of live
tumor (13.49 ± 4.85 g for Ad-CMV-HA-SSTR2 + A II,
15.49 ± 8.37 g for Ad-CMV-HA-SSTR2, and 14.99 ±
7.64 g for Ad-CMV-GFP; mean ± SD) and lack of en-
hancement of the necrotic center (22.61 ± 6.94 g for
Ad-CMV-HA-SSTR2 + A II, 27.38 ± 21.21 g for Ad-
CMV-HA-SSTR2, and 14.50 ± 1.29 g for Ad-CMV-
GFP; mean ± SD). The total tumor weights derived
from in vivo enhanced CT imaging (36.20 ± 7.21 g for
Ad-CMV-HA-SSTR2 + A II, 42.87 ± 24.84 g for Ad-
CMV-HA-SSTR2, and 29.48 ± 8.54 g for Ad-CMV-GFP;
mean ± SD) correlated well with the weights of excised
tumors (r = 0.97, n = 16)
In vivo assessment of reporter gene (Ad-CMV-HA-SSTR2)
expression in VX2 tumors after gene transfer with
angiotensin II
Three days after adenovirus infection, the animals were
injected via a marginal ear vein with 111In-octreotide,
which binds SSTR2. The following day, planar gamma
Fig. 1 Immunofluorescence. Indirect immunofluorescence demonstrates fluorescence, thus hSSTR2 expression, in cells infected with a Ad-CMV-hSSTR2
but not in the b uninfected negative control
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camera imaging (Fig. 4) demonstrated increased uptake
in tumors infected with Ad-CMV-HA-SSTR2 compared
to negative control Ad-CMV-GFP, and uptake appeared
greater if AII was also given with Ad-HA-SSTR2 com-
pared to Ad-HA-SSTR2 alone (Fig. 4). In vivo biodistri-
bution using a combination of CT and gamma camera
imaging demonstrated significantly greater uptake of
111In-octreotide in VX2 tumors infected with AII plus
Ad-CMV-HA-SSTR2 (0.025 ± 0.018; %ID/g mean ± SD)
compared to Ad-CMV-HA-SSTR2 (0.018 ± 0.011, %ID/g
mean ± SD) (p < 0.01; n = 6) alone or negative control
Ad-CMV-GFP (0.005 ± 006; %ID/g mean ± SD) (p < 0.01;
n = 6 AII plus Ad-CMV-HA-SSTR2, n = 4 Ad-CMV-
GFP, Fig. 4). Uptake was significantly higher in tumors
infected with Ad-CMV-HA-SSTR2 alone versus Ad-
CMV-GFP (p < 0.004, n = 6 and n = 4), respectively. Nec-
rotic regions of dead cells should not express genes, and
consistent with this, we have shown previously that
background uptake is found in areas of necrosis [1]. The
%ID/g without necrosis (areas of live/perfused tissue)
was significantly higher than the %ID/g with necrosis in
tumors infected with AII plus Ad-CMV-HA-SSTR2
(0.062 ± 0.03; %ID/g mean ± SD) (p = 0.004; n = 6) and
Ad-CMV-HA-SSTR2 (0.044 ± 0.016, %ID/g mean ± SD)
(p = 0.006; n = 6) (Fig. 4c). No significant change was
observed in the animals injected with negative control
Ad-CMV-GFP (0.011 ± 0.006; %ID/g mean ± SD).
Ex vivo evaluation of the radiotracer biodistribution
demonstrated significantly higher levels of 111In-octreo-
tide in tumors infected with AII plus Ad-CMV-HA-
SSTR2 (0.039 ± 0.014; %ID/g mean ± SD) compared to
tumors infected with Ad-CMV-HA-SSTR2 (0.022 ±
0.008, %ID/g mean ± SD) (p = 0.002; n = 6) or negative
control Ad-CMV-GFP (0.009 ± 0.0032; %ID/g mean ±
SD) (p = 0.004; n = 6 AII plus Ad-CMV-HA-SSTR2, n = 4
Ad-GFP); ex vivo %ID/g of Ad-CMV-HA-SSTR2 was also
significantly greater compared to control Ad-CMV-GFP
(p = 0.015; n = 6 Ad-CMV-HA-SSTR2, n = 4 Ad-GFP)
(Fig. 5a). This corresponded to in vivo biodistribution
findings. Thus, administration of AII significantly in-
creased tumor transgene expression. As expected, the
kidneys exhibited the highest uptake of 111In-octreotide
compared to other organs since the normal route of ex-
cretion for the radioligand is primarily through the kid-
neys with secondary routes via the liver and the
intestines (Fig. 5b). Western blot for the HA tag showed
HA-SSTR2 expression in tumors infected with Ad-
CMV-HA-SSTR2. Tumors infected with AII plus Ad-
CMV-SSTR2 showed the highest HA-SSTR2 expression
(top panel Fig. 5b).
Discussion
Clinical trials of gene therapy most commonly target
cancer and most commonly utilize adenovirus as the
Fig. 2 Angiography. Representative fluoroscopic images. The
vasoconstrictor angiotensin II (2.5 μg/ml) was administered through
the femoral artery to the tumor. Baseline blood flow was seen
before AII injection (a). A “tumor blush” consistent with increased
tumor blood flow was seen after AII administration (b)
Fig. 3 Representative transverse in vivo CT images of a rabbit hind
leg with VX2 tumors. a Unenhanced (without contrast) CT image
acquired 2 weeks after adenovirus injection. Tumors appear as areas
of low attenuation (arrows) and are relatively difficult to visualize. b
Contrast-enhanced CT image showing well-defined peripheral rim
enhancement of each tumor (solid white arrows). Areas of unenhanced
necrosis (central low attenuation material) are seen inside the tumor,
as indicated by the dotted white arrows
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vector [23]. Two of the major limitations for gene ther-
apy are delivery and an inability to monitor exogenous
gene expression in vivo. Using a SSTR2-based reporter
system, we demonstrate that angiotensin II can be used
to increase gene expression upon intra-arterial adeno-
virus delivery. For these experiments, a large animal
model was utilized as a bridge to translation since it en-
abled the use of catheterization techniques and imaging
equipment employed in the clinic. For imaging the re-
porter, an FDA-approved radiopharmaceutical was used.
To the best of our knowledge, this is the first study to
demonstrate the efficacy of angiotensin II in improving
gene expression upon intra-arterial delivery of adeno-
virus in a large animal model.
The use of a large animal model in this study allowed
for selective vascular access, enabling vascular manipula-
tion for augmenting intra-arterial gene delivery. This is
possible because the catheter can be manipulated under
fluoroscopic image guidance into the artery feeding the
tumor for injecting the adenovirus. This type of vascular
access is difficult to perform in mouse models due to
the smaller vessel size. IA delivery is already commonly
performed in patients, for example, for those suffering
from arteriovenous malformation (AVM), liver metasta-
ses, muscle disease, or brain tumors.
A vector may be delivered via several routes such as
by direct injection into the tumor, via inhalation, intra-
venously, or intra-arterially. Gnant et al. [24] showed
tumor-specific gene delivery is possible after systemic in-
jection of a thymidine kinase-negative vaccinia virus vec-
tor in a rabbit liver metastasis model. However, systemic
delivery such as via the venous system can result in vec-
tor loss due to first pass through organs such as the
lungs and the liver, where the vector may become en-
trapped or infect. Intra-arterial delivery may be used to
direct the vector to the tumor. For example, Barnett et
al. [25] performed adenoviral intra-arterial gene delivery
of anti-angiogenic endostatin in a syngeneic rat gliosar-
coma model and demonstrated transgene expression and
therapeutic efficacy. Similarly, Geschwind et al. [26] di-
rected the ATP production inhibitor, 3-bromopyruvate,
into liver-transplanted rabbit VX2 tumors via the IA deliv-
ery route and inhibited tumor growth. Soel et al. [27]
demonstrated in vivo transgene expression after IA deliv-
ery of a DNA/liposome/transferrin complex into VX2 tu-
mors in rabbit livers using β-galactosidase staining. On
Fig. 4 γ-Camera imaging data of VX2 tumors in rabbits. Representative gamma camera planar images of VX2 tumors (a) infected in vivo by IA
administration of AII + Ad-CMV-HA-SSTR2 and Ad-CMV-HA-SSTR2 and (b) infected in vivo by IA infusion of Ad-CMV-GFP control and Ad-CMV-HA-SSTR2
show increased 111In-octreotide uptake in tumors infected with AII + Ad-CMV-HA-SSTR2 compared to infection with Ad-CMV-HA-SSTR2 and the control
Ad-CMV-GFP. c 111In-octreotide biodistribution in tumors normalized to tumor weight (%ID/g) calculated with (black bars) and without (gray
bars) necrosis using in vivo imaging from gamma camera and CT imaging. Uptake was higher in tumors infected with AII + Ad-CMV-HA-SSTR2
(n = 6) compared to control Ad-CMV-GFP (*p < 0.01, n = 4) and Ad-CMV-HA-SSTR2 (*p < 0.01, n = 6). The %ID/g without necrosis was significantly
higher than the %ID/g with necrosis in tumors infected with AII + Ad-CMV-HA-SSTR2 (#p < 0.004, n = 6) and Ad-CMV-HA-SSTR2 (#p < 0.006, n = 6)
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the other hand, Kim et al. [28] evaluated the feasibility of
an iodized oil emulsion system that can be used for che-
moembolization of hepatocellular carcinoma as a modifier
of non-viral gene transfer for IA gene delivery in hepatic
tumors. Although these studies support the therapeutic
success of IA gene delivery, in vivo quantification of gene
expression was not evaluated. Gene therapy via the IA
route has been proposed as a better alternative to other
routes, such as intra-tumoral injection, because IA deliv-
ery should allow for repeated dosing and widespread dis-
tribution within the tumor [11]. However, there have been
reports to the contrary, finding IA and IT routes leads to
similar levels of expression [1].
For the first time, we were able to both in vivo quan-
tify and improve expression upon adenovirus delivery
using angiotensin II. Fluoroscopic imaging demonstrated
increased tumor blush consistent with increased blood
flow to the tumor upon delivery with AII. This suggests
improved adenovirus delivery. We previously found in a
liver model that a 2.5 μg/ml dose of AII increased blood
flow, blood volume, and permeability surface product
suggesting that a strategy employing AII may improve
delivery; however, it also decreased the mean transit time
in VX2 tumors compared to normal tissue [11]. The
current study demonstrates that such a strategy employ-
ing AII can result in improved expression after adeno-
virus delivery. Our study is supported by Bilbao et al.
who using adenovirus with a lacZ insert noted AII at
one dose could increase lacZ expression detected by
histology in larger rat hepatomas but not smaller hepa-
tomas [29].
Our previous data that at the appropriate dose, AII
leads to a tumor blush with poorer delineation of small
vessels, consistent with their vasoconstriction, and dy-
namic contrast-enhanced imaging data demonstrating
that blood flow was diverted to the tumor [11] is con-
sistent with the proposed mechanism of action of AII
causing vasoconstriction of normal vessel arterioles but
not the abnormal vessels in tumors that lack functional
arterioles and have decreased number of AII receptors
[30]. This would preferentially lead to increased blood
flow and blood volume for adenovirus delivery; these
Fig. 5 Ex vivo analysis of 111In-octreotide biodistribution in VX2 tumors after adenoviral infection. a Graph showing significantly higher uptake in
tumors infected with AII + Ad-CMV-HA-SSTR2 compared to tumors infected with control Ad-CMV-GFP (*p < 0.004, n = 4) and Ad-CMV-HA-SSTR2
(*p < 0.002, n = 6). The ex vivo %ID/g of Ad-CMV-HA-SSTR2 was also significantly higher compared to that of control Ad-CMV-GFP (p = 0.015). b Graph
showing ex vivo organs and tumor biodistribution of 111In-octreotide in rabbits bearing VX2 tumors infected in vivo with AII + Ad-CMV-HA-SSTR2,
Ad-CMV-HA-SSTR2, or control virus. Increased uptake was seen in tumors infected with AII + Ad-CMV-HA-SSTR2 or Ad-CMV-HA-SSTR2 as compared to
tumors infected with control Ad-CMV-GFP (*p < 0.015, n = 4), which was also found by western blot analysis of HA-SSTR2 in tumors (inset)
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effects and increased permeability appear to be more
significant than the decreased mean transit time noted
on the prior study DCE-CT study [11]. Given that the
mechanism of action is via vascular manipulation, we
predict that the AII strategy is likely applicable to other
gene therapy vectors for improving gene delivery and ex-
pression to various sites in the body. For evaluating
strategies for improving gene expression, in vivo reporter
imaging technologies with potential for human use, such
as those that are SSTR2-based, are useful.
Exogenous HA-SSTR2 gene expression can be quanti-
fied in a mouse model using functional and anatomic
imaging [18–20]. Large animal models not only enable
vascular manipulation like in humans but also can grow
larger tumors with necrosis—as is found in patients. Ne-
crosis occurs in solid tumors in the setting of insufficient
blood supply during the natural history of the disease or
as a response to therapy. In a large animal model, we
found that necrosis could be identified on contrast-
enhanced CT and does not pool the radiopharmaceuti-
cal, rather only background uptake was noted [1]. Areas
of necrosis should not express the transferred gene.
Thus, in the present study, necrotic areas were excluded
from calculations of %ID/g, resulting in corrected, in-
creased expression in the remaining live tumor. Ex vivo
analysis confirmed increased expression upon intra-
arterial AII delivery with adenovirus delivery. Anatomic
and functional imaging also enables longitudinal quanti-
fication of expression upon SSTR2-based gene delivery
[1, 18]. Current findings further support the use of
SSTR2-based reporters for assessing methods to improve
gene delivery and expression with the ultimate goal of
improving gene therapy efficacy. The use of novel re-
porters, such as signaling deficient-SSTR2, has prospect-
ive utility since they are limited in their effects on
normal cell signaling and cellular responses, such as rep-
lication [31]. Moreover, expression of potential thera-
peutic genes may be evaluated by linking them to
SSTR2-based reporters. Thus, methods to noninvasively
monitor gene transfer using SSTR2-based reporters may
have wide applicability towards improving and assessing
gene therapy; further example applications may include
vector development, assessing promoter activity, and de-
signing dosing regimens.
Conclusions
In summary, our study demonstrates improved gene ex-
pression when using angiotensin II in combination with
adenovirus upon intra-arterial delivery in a large animal
model. Gene expression was measured using a SSTR2-
based reporter system that was visualized using clinical
machines and an FDA-approved radiopharmaceutical.
Thus, this paper addresses two fundamental needs of
gene therapy, improved delivery and monitoring of gene
expression. The findings suggest that intra-arterial deliv-
ery of angiotensin II with adenovirus augments expres-
sion and thus may improve gene therapy efficacy and
that SSTR2-based reporter imaging is useful in com-
paring methods for enhancing gene expression in vivo.
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